Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is an open, multi-dose, dose escalation and cohort expansion, phase Ⅰ study to
investigate the safety, tolerability, efficiency, pharmacokinetics, immunogenicity of SG001
in subjects with advanced tumours.